Teva Slapped With €60m Fine Over Unlawful EU Provigil Delay

Fine Closes ‘Pay-For-Delay’ Investigation That Began In 2011

Teva received a “package of commercial side-deals” for agreeing to halt generic competition to Cephalon’s Provigil (modafinil) throughout the EU, which it “would not have achieved without committing to staying out of the market,” according to findings by the European Commission.

EU Brussels
Teva committed to stay out of the modafinil markets "because of the substantial value transferred to it by Cephalon," the EC found. • Source: Shutterstock

Teva and its Cephalon affiliate have received fines totaling €60.5m ($72m) from the European Commission over an historic ‘pay-for-delay’ arrangement covering Cephalon’s Provigil (modafinil) that violated EU antitrust rules and caused “substantial harm to EU patients and healthcare systems by keeping prices high.”

The fine is the culmination of a near ten-year investigation by the European Commission, beginning in April 2011, weeks before...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Regulation

More from Policy & Regulation

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Policy&Regulation-Free: Article with different widgets

    Emerging CRISPR innovations, shifting regulatory landscapes, and rising partnerships are accelerating a paradigm shift in biotech pipelines

  • Overseas API Manufacturing Identified As Key Vulnerability In US Supply Chain

    After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.